Asia
Vita Life Sciences Expects H1 Sales to Increase From a Year Earlier
Vita Life Sciences (ASX:VLS) expects a pre-tax profit of AU$6.8 million to AU$7.3 million and sales of AU$46.3 million to AU$47.3 million for the half year ending June 30, according to a Friday filing with the Australian bourse.For the first half of 2025, the company booked a pre-tax profit of AU$6.8 million on sales of AU$45.5 million, per the filing.Vita Life Sciences said it expects "solid revenue growth" in the markets of Australia, Malaysia, and Singapore, partially offset by lower exports to China amid a shifting regulatory landscape and channel dynamics.
ASX:VLS
